Caveolin‑1 and dynamin‑2 overexpression is associated with the progression of bladder cancer
- Authors:
- Published online on: May 3, 2019 https://doi.org/10.3892/ol.2019.10310
- Pages: 219-226
Abstract
Introduction
Caveolae are small bulb-like invaginations (50–80 nm in diameter) in the plasma membrane, with a diverse array of signal transduction functions (1–3). Functioning as a signal-transducing platform, caveolae are actively involved in the transcellular transport of ligands and receptor molecules, forming a specialized transporting system that maintains the lipid content of plasma membranes via transcytosis (4). Caveolae have been implicated as crucial entities for cell-cell communication via the endocytosis of signaling molecules, in addition to their role as signaling platforms where membrane receptors, including G-protein-coupled receptors, reside. Disrupted signaling through key caveolar proteins results in various pathologies, including cardiomuscular diseases, lipodystrophy, and, most importantly, cancer (5). Caveolar proteins exert their dynamic role in maintaining cell growth, cell protection and overall cell function (6). Caveolae consist of complexes comprising different transmembrane proteins, including caveolin, cavin, dynamin-2, EH-domain containing 2 protein and protein kinase C and casein kinase substrate in neurons protein 2, among which caveolins are the core functional proteins (7). Cavins and caveolins (1–3) are the fundamental proteins that mediate caveolar organization. Caveolins provide a signaling platform for the coordination and interaction of different growth factor receptors, protein kinases and various intracellular signaling molecules (8). Dynamin-2, the product of the dynamin 2 (DNM2) gene, is a GTPase that directly interacts with caveolin-1, the product of the caveolin-1 (Cav-1) gene, mediating membrane scission, leading to endosome formation (9). Caveolin-1 and dynamin-2 are the key regulators of clathrin-independent endocytosis (10).
Among the caveolin proteins, caveolin-1 (molecular mass, ~21 kDa) is known to be a key protein of the caveolae complex that has an important role in maintaining cell metabolism, anchorage-dependent growth, motility and signaling, and the cellular microenvironment (11). In fulfilling these crucial roles in cell growth and maintenance, the altered expression and function of caveolin-1 is associated with oncogenic cell transformation, cell metastasis, invasion and tumorigenesis. Enhanced expression of Cav-1 promotes tumor growth and invasion, resulting in the metastasis of human breast cancer cells (12). Knockdown of Cav-1 was demonstrated to inhibit tumor growth and metastasis (13). Dynamin-2 (molecular mass ~100 kDa) is a GTPase that is actively involved in membrane fission during the endocytosis of cell-surface receptors and signaling molecules. The endosomes, also termed ‘caveosomes’, thus formed are continually recycled to the cell surface (14). This mechanism of protein expression on the cell membrane is disrupted in cancer cells. Dynamin-2 protein dysfunction results in the dysregulation of endosome recycling, causing an imbalanced expression of regulatory growth factor receptors, including epidermal growth factor receptor, on the cell surface, promoting aberrant cell growth, invasion and proliferation (15). Overexpression of Cav-1 and DNM2 has been demonstrated to be involved in cell lines of various types of cancer, including pancreatic, colon, lung, breast and prostate cancer (13,16–22).
Bladder cancer is the ninth most common cancer worldwide. Of all incident cases of different types of cancer in the Pakistani population during the year 2012 (n=148,041), the incidence rate of bladder cancer in the male population was 3,020, which was increased compared with that in the female population (n=946) (23). In muscle-invasive bladder cancers, 58 genetic mutations have been demonstrated to be causative factors for cancer progression in the bladder, and these are associated with low survival rates (24). There are a number of genetic alterations associated with bladder cancer progression. Overexpression, and genetic mutation, of several different genes that are critical in cell cycle regulation, apoptosis, signal transduction and angiogenesis have been identified, among which mutants of tumor protein (p53), fibroblast growth factor 3, Janus kinase/signal transducers and activator of transcription, hypoxia-inducible factor, retinoblastoma protein 1, HRas proto-oncogene, GTPase (also known as transforming protein p21), tuberous sclerosis 1, telomerase reverse transcriptase, and ubiquitin carboxyl-terminal hydrolase BAP1 have been identified and studied (24–26). Furthermore, numerous other previously identified genetic alterations are associated with a poor prognostic outcome, and these are currently undergoing validation (27). Regulatory genes that are involved in cell cycle regulation and apoptosis have been validated as combined prognostic markers for bladder cancer, although these are under investigation for use as single markers associated with urothelial carcinoma (28). However, genes/proteins that are involved in cell surface communication with the extracellular environment, cell-to-cell communication, endocytosis, and exocytosis are far more susceptible to cancer development compared with intercellular proteins, particularly caveolar proteins (29). The upregulation of caveolar proteins has been demonstrated for various different types of cancer, whereas only a few cancer types have been associated with their downregulation (30,31). Despite the contradictory roles identified for caveolin-1 in different types of cancer, overexpression of Cav-1 has been described for the majority of human cancer types. Previous studies investigating the overall clinical value of Cav-1, and its association with tumor aggressiveness, size, stage, grade and differentiation, suggest that it may serve as a good candidate prognostic marker for a majority of cancer types, including bladder cancer (32,33). By contrast, the gene expression of DNM2, and its association with cancer progression, has yet to be fully investigated. However, the identification and validation of the prognostic panel of disease markers for bladder cancer is required. A number of studies have explored the expression profiling of bladder cancer in humans, in which genome coding sequences were decoded for evaluating genetic alterations associated with the disease, and subsequently, the prognostic marker panel could be selected. However, one disadvantage in terms of ensuring its reproducibility is that this widely applied approach is highly expensive (34–36).
Bladder cancer, based on its metastatic ability to spread to other parts of the body, is divided into 4 stages (stages I–IV) according to the tumor-node-metastasis (TNM) staging system (37). Physiologically, bladder tumors are essentially categorized into 2 grades: Low-grade papillary urothelial carcinoma and high-grade papillary urothelial carcinoma, according to the World Health Organization/International Society of Urological Pathology classification system, published in 2004 (38). Previous studies have demonstrated altered expression levels of Cav-1 and DNM2 in bladder cancer cell lines (33,39–41). Therefore, the present study aimed to investigate the degree of correlation of gene expression in comparing between the Cav-1 and DNM2 genes in bladder cancer tumor samples, specifically with respect to the progressiveness of the tumors. The results obtained revealed that the significant correlation between the overexpression of Cav-1 and DNM2 in bladder tumors was critical for cancer development, and for tumor stage and grade progression. The overexpression of these 2 genes could be considered clinically relevant and may prove as candidate risk factors for bladder cancer progression.
Materials and methods
Tumor sampling
The present study was approved by the Ethical Review Board of COMSATS University Islamabad (Islamabad, Pakistan; approval no. CIIT/Bio/ERB/18/76). Samples were collected between July, 2015 and March 2017. Tumor and normal tissue samples were excised from patients with bladder cancer post-surgery, following transurethral resection of bladder tumor (TURBT) surgery. Signed written consent was obtained from all the patients involved in the present study (n=66; male=47; female=19). The patients' age ranged between 30 and 65 years and the median age was 43 years. The histopathological histories of the patients were confirmed by the Pathology Laboratory, Pakistan Institute of Medical Science (PIMS) (Islamabad, Pakistan) and Shifa International Hospital (Islamabad, Pakistan). Paired samples of tumors with their adjacent normal tissues were obtained. Normal tissue samples were used as controls. The tumor staging and grading was assessed by the team of urologists at Pathology Laboratory, Department of Urology, PIMS. The TNM system of staging was applied for evaluation of the tumor stage. The revised guidelines by National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer and American Society of Clinical Oncology (ACSO) 2015–2018 were followed during grading and staging of tumor samples (42).
Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
Tissues extracted from the patients were stored in RNAlater® (Ambion; Thermo Fisher Scientific, Inc.) at 4°C in a refrigerator. RNA extraction was performed using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.) reagent according to the manufacturer's protocol (43). Subsequently, cDNA synthesis was performed, followed by RNA quantification. The minimum concentration of RNA used in these experiments was 1–2 µg for cDNA synthesis. Thermo Scientific RevertAid First Strand cDNA Synthesis kit was used for cDNA synthesis (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocols. The PrimerQuest tool (Integrated DNA Technologies, Inc.) was used to design the primers, which were subsequently altered manually to meet the required specifications for RT-qPCR. The forward primer for Cav-1 (NM_001753.4) was designed to span exon 2 and the junction with exon 3, and the reverse primer was selected from exon 3, whereas the primer set for DNM2 (NM_001005360.2) was designed based on the intron flanking exons 6 and 7 (Table I). Tubulin 3 was used as an endogenous marker for evaluating changes in the expression levels of Cav-1 and DNM2. In silico PCR (University of California Santa Cruz) was performed to ensure amplification of the 2 target genes. RT-qPCR using the Applied Biosystems™ StepOnePlus™ RealTime PCR system (Applied Biosystems, Inc.; Thermo Fisher Scientific, Inc.) was performed for the Cav-1 and DNM2 genes under standard conditions, as specified by the protocol. The concentration of cDNA was rounded up to 2 µg/µl for each sample, and the total volume per reaction was adjusted to 25 µl with SYBR™ Green Master mix (Maxima Syber Green/ROX qPCR Master mix; Thermo Fisher Scientific, Inc.). The RT-qPCR conditions consisted of an initial incubation at 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 30 sec, an annealing with primer at 57°C for 30 sec and extension at 72°C for 30 sec. Final extension was performed at 72°C for 10 min.
 | Table I.Primer sequence used for reverse transcription quantitative polymerase chain reaction analysis. |
Gene expression analysis
The relative expression levels of Cav-1 and DNM2 were calculated using the 2−ΔΔCq method (44). Using TUBB3 as the control reference gene (45), relative differences in gene expression were obtained in terms of the fold increase in expression. To obtain the expression data, the Cq values of the Cav-1 and DNM2 genes were normalized against the Cq value for endogenous TUBB3.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc.) and OriginPro 2017 (OriginLab Corporation) software. Contingencies of the patients' data were determined using Fisher's exact two-tailed test, and the correlation between the gene expression patterns was assessed using Pearson's correlation coefficient test. Depending on the experiment, the statistical significance of the resulting data was determined using either the Wilcoxon test or one way analysis of variance followed by the Tukey's honest significant difference post-hoc test. P<0.05 was considered to indicate a statistically significant difference.
Results
Tumor histopathology
Tumor staging was evaluated by the Pathology Laboratory of PIMS, according to the TNM system but incorporating the revisions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer and ACSO 2015–2018 (42). Distribution of the tumor grade and stage data by sex and age groups was statistically analyzed (Table II). In October 2017, The Cancer Genome Atlas (TCGA) published the prevalence and incidence rates of bladder cancer (https://cancergenome.nih.gov/newsevents/newsannouncements/bladder-cancer_2017), which was increased in the male population compared with females, and, in terms of underlying causes, smoking was demonstrated to be the major factor in that study (46). A comprehensive molecular characterization study was also performed by TCGA research network, which described the genetic alterations associated with bladder cancer (24). In the present study, a significant difference was identified in terms of the pathology between the sexes in the different age groups (P=0.0024; Table II). A number of different diseases were identified in patients from both age groups, but their associations with bladder cancer were not statistically significant. Conversely, the risk factors of active smoking (P=0.0135) and passive smoking (P=0.0316) were identified to be significantly associated with bladder cancer (Table III).
Cav-1 and DNM2 expression
In the tumor samples, the expression levels of Cav-1 and DNM2 were experimentally analyzed using RT-qPCR. The expression of Cav-1 in the tumor samples was increased by 8.88-fold overall compared with the normal tissues. Similarly, the expression level of DNM2 was also increased by 8.6-fold compared with the normal adjacent, or control, tissues (P<0.001). As demonstrated in Fig. 1, boxplots of normalized (mean ± standard error of the mean) gene expression of Cav-1 and DNM2 revealed a significant increase in gene expression in tumor tissues compared with the adjacent normal tissue. Previous studies also demonstrated increased expression levels of Cav-1 and DNM2 in different cancer cell lines (39,41). The genes exhibited enhanced expression levels in bladder tumor samples concomitantly with the progression of cancer. A significant difference in expression levels was observed comparing between low- and high-grade tumors (P<0.0001; Fig. 2). A similar trend was also observed with respect to the cancer stages. Alterations in Cav-1 and DNM2 expression were revealed to be associated with the cancer stage, as indicated in Fig. 3A and B. These results demonstrated that the expression levels of the two genes increased concomitantly with the development of higher disease stages. However, highly significant differences in the expression of Cav-1 and DNM2 were observed when stage I tumors were compared with stage II tumors (P<0.0001), and when stage II tissues were compared with stage III samples (P<0.0001). A similar difference was also identified when comparing stage I tumors with stage III tumors (P<0.0001; Fig 3A and B).
Correlation between Cav-1 and DNM2
The Cav-1 and DNM2 genes serve an important role in the functionality of clathrin-independent endocytosis. Altered expression levels of the genes has been demonstrated to be associated with pathological outcomes (32,47). In the present study, the expression of Cav-1 was clearly correlated with the expression of DNM2 (P<0.0001; Pearson's coefficient, r=0.8617; Fig. 4A and B). The segregation of DMN1/Cav-1 correlation data into two clusters additionally confirmed the increased expression of the 2 genes in high-grade tumors compared with low-grade tumors demonstrated in Fig. 2.
Discussion
Cav-1 is a key component of caveolae in terms of their formation, arrangement and function. Together with DNM2, Cav-1 initiates the process of endocytosis (32). Cav-1 has been demonstrated to be a critical component of numerous types of cancer, including breast, lung, colorectal, cervical and pancreatic cancer (21,48–50). Previous studies have presented accumulating evidence revealing that cancer cells are prone to modifying the microenvironment of the tumor, inducing the adjacent cells to become malignant (51–54). In this regard, Cav-1 is implicated as an important protein that affects the metabolic activity of cells during cancer progression (55). The results of the present study revealed a progressive increase in the expression level of Cav-1 concomitant with the higher stages of bladder cancer. As the stage of bladder cancer progresses, cells that are cancerous maintain their survival by utilizing key proteins that provide them with the necessarily favorable environment to grow, invade and migrate via regulating the respective functional proteins. Increased expression levels of Cav-1 in higher grades of bladder cancer enable an increased potential of the cells to invade and proliferate (56). Therefore, in the present study, the high-grade tumors were revealed to have comparatively enhanced expression levels of Cav-1 compared with low-grade tumors.
Altered expression of DNM2 also serves a role in cancer progression. DNM2 has been implicated as a therapeutic target for cervical cancer: In Hela cells, dynamin-2 inhibitors have been demonstrated to cause decreased migration and invasion via decreasing the expression of matrix metallopeptidase 9, thereby lowering the rate of cell proliferation (57). Similar to Cav-1, an increase in the expression of DNM2 has been demonstrated to correspond to advances in the tumor stage (19). In the present study, the expression levels of DNM2 and Cav-1 genes exhibited a marked correlation with the progression of bladder tumor stage. These results demonstrated that an increase in the expression of these 2 genes may stimulate the tumors to proliferate, invade and metastasize to different adjacent organs. Cancer cells have their own modified microenvironment through which they communicate with adjacent cells for growth proliferation and survival (5).
Summarizing what is known concerning cancer progression, cellular communication is the hallmark of tumorigenesis. Interactions with signaling molecules provide a major focus for disrupted signaling. Cav-1, being a key protein of the caveolae, is critical for cancer development, as it directly interacts with signaling proteins, including phosphoinositide 3-kinase, Src, phospholipases, extracellular signal-regulated kinase, G-proteins, endothelial nitric oxide synthase, adenylyl cyclase, protein kinase C, p53 and cell division control protein 42 homolog, and is involved in signal transduction cascades (13,58,59). Dysfunction of Cav-1, resulting from the aberrant expression of the gene, triggers the activation of various growth-promoting pathways (4,11). Previous studies have suggested overexpression of Cav-1 to be a cause of cancer progression (32,60,61). Similarly, together with Cav-1, DNM2 also mediates effects on cancer formation and progression. The 2 proteins are involved in the endocytosis of a number of receptor proteins, ligands and signaling molecules (19,62). However, it has been suggested that there are several other interlinked signaling pathways that, in response to overexpression of Cav-1 and DNM2, may be activated and/or deactivated, resulting in tumor formation (63).
Although the present study has described the genetic expression of the target genes, there were several limitations. Firstly, the samples were not obtained from stages 0a and 0is, the 2 preliminary stages of bladder cancer, or the final stage, stage IV, as patients are not subjected to TURBT at the initial or the last stages of disease. Consequently, all the patients within the study cohort were diagnosed with mid-stage disease, for which TURBT surgery is available. There is an urgent requirement for diagnoses of bladder cancer at early stages. The target genes selected for the present study may be considered as good prognostic marker for bladder cancer. If bladder tumor samples from the initial to the final stages had been available for analysis, then the differences in expression of the target genes in the tumor samples could have been validated more comprehensively. Future studies will aim to investigate the protein expression of the target genes in bladder tumor samples, and to explore the functional disruptions due to overexpression of the target genes/proteins that may have caused tumor aggressiveness during cancer progression. In the present study, the observed association of the increased expression levels of Cav-1 and DNM2 with advancing tumor stage could be considered as a risk factor for bladder cancer, which may additionally aid tumor and disease prognosis, and provide potentially novel treatment options.
Acknowledgements
Not applicable.
Funding
The present study was supported by the COMSATS Research Grant Program (grant no. 16/54/CRGP/CIIT/IBD/15/791) by COMSATS University Islamabad.
Availability of data and materials
All data generated or analyzed during this study are included in this published article.
Authors' contributions
SAR was responsible for conception and design of the study, performed the data analysis and its interpretation, and prepared the manuscript. STAS refined the research design, and performed data analysis and interpretation. KS assisted with the experimental protocols and data acquisition. AY, AK, MN and AM evaluated the tumor samples and prepared the histopathological reports of the tumors. AT and NB contributed towards the research design, and secured collaborations with the hospitals from which the samples were obtained. MJK and AH also assisted with the conception of the study, and with research supervision.
Ethics approval and consent to participate
The study was approved by the ethical review board of COMSATS Institute of Information Technology (approval no. CIIT/Bio/ERB/18/76). Written signed consent was obtained from the patients involved.
Patient consent for publication
Written signed consent was obtained from the patients involved.
Competing interests
The authors declare that they have no competing interests.
References
|
Bastiani M and Parton RG: Caveolae at a glance. J Cell Sci. 123:3831–3836. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Anderson RG: The Caveolae membrane system. Annu Rev Biochem. 67:199–225. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Yamada E: The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol. 1:445–458. 1955. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng JPX and Nichols BJ: Caveolae: One function or many? Trends Cell Biol. 26:177–189. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Martinez-Outschoorn UE, Sotgia F and Lisanti MP: Caveolae and signalling in cancer. Nat Rev Cancer. 15:225–237. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Parton RG and Pozo MA: Caveolae as plasma membrane sensors, protectors and organizers. Nat Rev Mol Cell Biol. 14:98–112. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ludwig A, Howard G, Mendoza-Topaz C, Deerinck T, Mackey M, Sandin S, Ellisman MH and Nichols BJ: Molecular composition and ultrastructure of the caveolar coat complex. PLoS Biol. 11:e10016402013. View Article : Google Scholar : PubMed/NCBI | |
|
Patel HH, Murray F and Insel PA: Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxicol. 48:359–391. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yao Q, Chen J, Cao H, Orth JD, McCaffery JM, Stan RV and McNiven MA: Caveolin-1 interacts directly with dynamin-2. J Mol Biol. 348:491–501. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mayor S, Parton RG and Donaldson JG: Clathrin-independent pathways of endocytosis. Cold Spring Harb Perspect Biol. 6:a0167582014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu P, Rudick M and Anderson RG: Multiple functions of caveolin-1. J Biol Chem. 277:41295–41298. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Urra H, Torres VA, Ortiz RJ, Lobos L, Díaz MI, Díaz N, Härtel S, Leyton L and Quest A: Caveolin-1-enhanced motility and focal adhesion turnover require tyrosine-14 but not accumulation to the rear in metastatic cancer cells. PLoS One. 7:e330852012. View Article : Google Scholar : PubMed/NCBI | |
|
Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA, Chen CS, Ludwig T, et al: Caveolin-1 is associated with tumor progression and confers a multi-modality resistance phenotype in pancreatic cancer. Sci Rep. 5:108672015. View Article : Google Scholar : PubMed/NCBI | |
|
Hinshaw JE: Dynamin and its role in membrane fission. Annu Rev Cell Dev Biol. 16:483–519. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F and Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 366:2–16. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Basu Roy UK, Rial NS, Kachel KL and Gerner EW: Activated K-RAS increases polyamine uptake in human colon cancer cells through modulation of caveolar endocytosis. Mol Carcinog. 47:538–553. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Feng H, Liu KW, Guo P, Zhang P, Cheng T, McNiven MA, Johnson GR, Hu B and Cheng SY: Dynamin 2 mediates PDGFRalpha-SHP-2-promoted glioblastoma growth and invasion. Oncogene. 31:2691–2702. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Eppinga RD, Krueger EW, Weller SG, Zhang L, Cao H and McNiven MA: Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. Oncogene. 31:1228–1241. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Meng J: Distinct functions of dynamin isoforms in tumorigenesis and their potential as therapeutic targets in cancer. Oncotarget. 8:41701–41716. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Alshenawy HA and Ali MA: Differential caveolin-1 expression in colon carcinoma and its relation to E-cadherin-beta-catenin complex. Ann Diagn Pathol. 17:476–482. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Patlolla JM, Swamy MV, Raju J and Rao CV: Overexpression of caveolin-1 in experimental colon adenocarcinomas and human colon cancer cell lines. Oncol Rep. 11:957–963. 2004.PubMed/NCBI | |
|
Tanase CP: Caveolin-1: A marker for pancreatic cancer diagnosis. Expert Rev Mol Diagn. 8:395–404. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sarwar MR and Saqib A: Cancer prevalence, incidence and mortality rates in Pakistan in 2012. Cogent Med. 4:12887732017. View Article : Google Scholar | |
|
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, et al: Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 171:540–556.e525. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X and Zhang Y: Bladder cancer and genetic mutations. Cell Biochem Biophys. 73:65–69. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang K, Liu T, Liu C, Meng Y, Yuan X, Liu L, Ge N, Liu J, Wang C, Ren H, et al: TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer. Oncologist. 20:263–269. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao M, He XL and Teng XD: Understanding the molecular pathogenesis and prognostics of bladder cancer: An overview. Chin J Cancer Res. 28:92–98. 2016.PubMed/NCBI | |
|
Rosenblatt R, Jonmarker S, Lewensohn R, Egevad L, Sherif A, Kälkner KM, Nilsson S, Valdman A and Ullén A: Current status of prognostic immunohistochemical markers for urothelial bladder cancer. Tumour Biol. 29:311–322. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sever R and Brugge JS: Signal transduction in cancer. Cold Spring Harb Perspect Med. 5:a0060982015. View Article : Google Scholar : PubMed/NCBI | |
|
Massey KA and Schnitzer JE: Caveolae and cancer. Recent Results Cancer Res. 180:217–231. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta R, Toufaily C and Annabi B: Caveolin and cavin family members: Dual roles in cancer. Biochimie. 107:188–202. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen D and Che G: Value of caveolin-1 in cancer progression and prognosis: Emphasis on cancer-associated fibroblasts, human cancer cells and mechanism of caveolin-1 expression (review). Oncol Lett. 8:1409–1421. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Soria F, Lucca I, Moschini M, Mathieu R, Rouprêt M, Karakiewicz PI, Briganti A, Rink M, Gust KM, Hassler MR, et al: Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. Urol Oncol. 35:356–362. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Sanchez-Carbayo M, Socci ND, Lozano J, Saint F and Cordon-Cardo C: Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 24:778–789. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Rosser CJ, Liu L, Sun Y, Villicana P, McCullers M, Porvasnik S, Young PR, Parker AS and Goodison S: Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol Biomarkers Prev. 18:444–453. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Dyrskjot L, Zieger K, Kruhoffer M, Thykjaer T, Jensen JL, Primdahl H, Aziz N, Marcussen N, Møller K and Orntoft TF: A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res. 11:4029–4036. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, et al: Melanoma staging: Evidence-based changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 67:472–492. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Pan CC and Chang YH: The 2004 World Health Organization/International Society of Urological Pathology classification system for non-muscle-invasive bladder cancer. Urol Sci. 24:96–100. 2013. View Article : Google Scholar | |
|
Zhang Y, Nolan M, Yamada H, Watanabe M, Nasu Y, Takei K and Takeda T: Dynamin2 GTPase contributes to invadopodia formation in invasive bladder cancer cells. Biochem Biophys Res Commun. 480:409–414. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ruan J and Weng ZL: Analysis of the relationship between expression of caveolin-1 and prognosis in bladder transitional cell carcinoma. Zhonghua Zhong Liu Za Zhi. 32:429–431. 2010.(In Chinese). PubMed/NCBI | |
|
Liang W, Hao Z, Han JL, Zhu DJ, Jin ZF and Xie WL: CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition. Urol Oncol. 32:855–863. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, et al: Bladder cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 15:1240–1267. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Rio DC, Ares M Jr, Hannon GJ and Nilsen TW: Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc. 2010.pdb.prot5439, 2010. View Article : Google Scholar | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Bangaru ML, Park F, Hudmon A, McCallum JB and Hogan QH: Quantification of gene expression after painful nerve injury: Validation of optimal reference genes. J Mol Neurosci. 46:497–504. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer. Net Editorial Board: Bladder Cancer-Risk Factors. https://www.cancer.net/cancer-types/bladder-cancer/risk-factorsJune 25–2012 | |
|
Aghbolaghi AG and Lechpammer M: A rare case of centronuclear myopathy with DNM2 mutation: Genotype-phenotype correlation. Autops Case Rep. 7:43–48. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Duregon E, Senetta R, Bertero L, Bussolati B, Annaratone L, Pittaro A, Papotti M, Marchiò C and Cassoni P: Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas. Tumour Biol. 39:10104283176943112017. View Article : Google Scholar : PubMed/NCBI | |
|
Lee SW, Reimer CL, Oh P, Campbell DB and Schnitzer JE: Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 16:1391–1397. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Lin M, DiVito MM, Merajver SD, Boyanapalli M and van Golen KL: Regulation of pancreatic cancer cell migration and invasion by RhoC GTPase and Caveolin-1. Mol Cancer. 4:212005. View Article : Google Scholar : PubMed/NCBI | |
|
Friedl P and Alexander S: Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell. 147:992–1009. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kang HW, Kim WJ and Yun SJ: The role of the tumor microenvironment in bladder cancer development and progression. Transl Cancer Res. 6 (Suppl):S744–S758. 2017. View Article : Google Scholar | |
|
Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S and Lisanti MP: Caveolin-1 and cancer metabolism in the tumor microenvironment: Markers, models, and mechanisms. Annu Rev Pathol. 7:423–467. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, et al: Role of tumor microenvironment in tumorigenesis. J Cancer. 8:761–773. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Nwosu ZC, Ebert MP, Dooley S and Meyer C: Caveolin-1 in the regulation of cell metabolism: A cancer perspective. Mol Cancer. 15:712016. View Article : Google Scholar : PubMed/NCBI | |
|
Diaz-Valdivia N, Bravo D, Huerta H, Henriquez S, Gabler F, Vega M, Romero C, Calderon C, Owen GI, Leyton L and Quest AF: Enhanced caveolin-1 expression increases migration, anchorage-independent growth and invasion of endometrial adenocarcinoma cells. BMC Cancer. 15:4632015. View Article : Google Scholar : PubMed/NCBI | |
|
Girard E, Paul JL, Fournier N, Beaune P, Johannes L, Lamaze C and Védie B: The Dynamin Chemical Inhibitor Dynasore Impairs Cholesterol Trafficking and Sterol-Sensitive Genes Transcription in Human HeLa Cells and Macrophages. PLoS One. 6:e290422011. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YY, Jeon HK, Lee J, Do IG, Choi CH, Kim TJ, Kim BG, Bae DS, Kim YC and Lee JW: Dynamin 2 inhibitors as novel therapeutic agents against cervical cancer cells. Anticancer Res. 36:6381–6388. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Galbiati F, Volonte D, Liu J, Capozza F, Frank PG, Zhu L, Pestell RG and Lisanti MP: Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Mol Biol Cell. 12:2229–2244. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Nunez-Wehinger S, Ortiz RJ, Diaz N, Diaz J, Lobos-Gonzalez L and Quest AF: Caveolin-1 in cell migration and metastasis. Curr Mol Med. 14:255–274. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sun DS, Hong SA, Won HS, Yoo SH, Lee HH, Kim O and Ko YH: Prognostic value of metastatic tumoral caveolin-1 expression in patients with resected gastric cancer. Gastroenterol Res Pract. 2017:59051732017. View Article : Google Scholar : PubMed/NCBI | |
|
Ge Z, Gu Y, Han Q, Zhao G, Li M, Li J, Chen B, Sun T, Dovat S, Gale RP and Song C: Targeting HIGH DYNAMIN-2 (DNM2) expression by restoring ikaros function in acute lymphoblastic leukemia. Sci Rep. 6:380042016. View Article : Google Scholar : PubMed/NCBI | |
|
Quest AF, Gutierrez-Pajares JL and Torres VA: Caveolin-1: An ambiguous partner in cell signalling and cancer. J Cell Mol Med. 12:1130–1150. 2008. View Article : Google Scholar : PubMed/NCBI |
